索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]周小玲,陈珏,李攀.经皮导管射频消融去肾脏交感神经术治疗顽固性高血压的治疗现状[J].国际心血管病杂志,2016,04:221-223.
点击复制

经皮导管射频消融去肾脏交感神经术治疗顽固性高血压的治疗现状(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年04期
页码:
221-223
栏目:
综述
出版日期:
2016-07-20

文章信息/Info

Title:
-
作者:
周小玲; 陈珏; 李攀
200433 上海,第二军医大学长海医院门诊部(周小玲,陈 珏); 心血管内科(李 攀)
Author(s):
-
关键词:
射频消融术; 高血压; 介入治疗; 肾交感神经
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.04.009
文献标识码:
-
摘要:
对于顽固性高血压患者,药物治疗不能较好地控制血压。肾脏交感神经活性增强是高血压发生、发展和靶器官损害的重要危险因素。近年来研究表明,经皮导管射频消融去肾交感神经术有助于治疗顽固性高血压。
Abstract:
-

参考文献/References

[1] Kearney PM,Whelton M,Reynolds K,et al.Global burden of hypertension:analysis of worldwide data[J].Lancet,2005,365(9455):217-223.
[2] 瞿 屹,胡建平,孔灵芝,等.中国居民高血压造成冠心病和脑卒中的经济负担研究[J].中华流行病学杂志,2006,27(9):744-747.
[3] 王增武,王 馨,李 贤,等.中年人群高血压患病率及控制状况的演变趋势[J].中华高血压杂志,2008,16(11):1033-1036.
[4] Calhoun DA, Jones D, Textor S, et al. Resistant hypertension:diagnosis,evaluation and treatment.A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research[J].Hypertension, 2008, 51(6):1403-1419.
[5] Mahfoud F, I Iimmel F, Ukena C, et al. Treatment strategies for resistant arterial hypertension[J].DtschArztebl Int, 2011,108(43):725-731.
[6] Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention,detection,evaluation,and treatment of high blood pressure[J].Hypertension, 2003,42(6):1206-1252.
[7] Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension[J].Arch Intern Med, 2008,168(21):2340-2346.
[8] Benjelloun H, Aboudrar S, Jroundi I, et al. Sympathetic response in primary hypertension[J].Ann Cardiol Angeiol(Paris), 2009,58(3):139-143.
[9] 熊楠青,李 剑,罗心平.肾动脉交感神经丛射频消融治疗顽固性高血压[J].国际心血管病杂志,2012,39(1):11-13.
[10] 张 奇,张瑞岩.经皮导管肾交感神经消融术治疗顽固性高血压进展[J].国际心血管病杂志,2012,39(6):324-326.
[11] Tam GM, Yan BP, Shetty SV, et al. Transcatheter renal artery sympathetic denervation for resistant hypertension: an old paradigm revisited[J].Int J Cardiol, 2013, 164(3): 277-281.
[12] Zhang ZH, Yu Y, Kang YM, et al. Aldosterone acts centrally to increase brain rennin-angiotensin system activity and oxidative stress in normal rats[J].Am J Physiol Heart Circ Physiol, 2008, 294(2):H1067-H1074.
[13] Argacha JF, Van de Borne P. Renaldenervation: new treatment for refractory hypertension[J].Rev Med Brux, 2012,33(4):292-294.
[14] Imbalzanoa E, Ceravolob R, Vatrano M, et al. Renal denervation and hypertension resistant drug treatment in patient with renal artery accessory[J].Int J Cardiol, 2014,171(1):e8-e9.
[15] Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study[J].Lancet,2009,373(9671):1275-1281.
[16] Esler MD, KrumH, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension(the Symplicity HTN-2 trial): a randomized controlled trial[J].Lancet, 2010, 376(9756): 1903-1909.
[17] Worthley SG, Tsioufis CP, Worthley MI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN Ⅰ trial[J].Eur Heart J, 2013, 34(28): 2132-2140.
[18] Sievert H, Schofer J, Ormiston J, et al.Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study[J].EuroIntervention, 2015, 10(10): 1213-1220.
[19] Schlaich MP, Sobotka PA, Krum H, et al. Renalsympatheticnerve ablation for uncontrolled hypertension[J].N Engl J Med, 2009, 361(9): 932-934.
[20] Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympatheticdenervation on glucose metabolism in patients wihtresistanthypertension: apilot study[J].Circulation, 2011,123(18):1940-1946.
[21] Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD[J].J Am Soc Nephrol, 2012,23(7):1250-1257.
[22] Sapoval M, Azizi M. Renal artery denervation for the treatment of resistant hypertension. Update after Medtronic announcement that its Symplicity HTN3 study failed to meet its primary efficacy end point[J].Diagn Interv Imaging,2014, 95(4):353-354.
[23] 廖康腊,秦 俭.经导管射频消融去肾交感神经术的现状[J].心血管病学进展,2013,34(1): 90-93.
[24] 蒋雄京.中国高血压联盟关于经皮经导管射频消融去肾交感神经术治疗难治性高血压的立场与建议[J].中国医学前沿杂志(电子版),2013,5(9):51-56.
[25] van Amsterdam WA,Blankestijn PJ, Goldschmeding R, et al. The morphological substrate for Renal Denervation: Nerve distribution patterns and parasympathetic nerves.A post-mortem histological study[J].Ann Anat, 2016,204:71-79.

备注/Memo

备注/Memo:
基金项目:上海市浦江人才计划项目(14PJD003); 国家自然科学基金青年科学基金项目(8140020849) 作者单位:200433 上海,第二军医大学长海医院门诊部(周小玲,陈 珏); 心血管内科(李 攀) 通信作者:李 攀,Email:smmulipan@163.com
更新日期/Last Update: 2016-07-20